Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04803994 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Apr 1, 2025 to Jul 2027
    • Study sites: 68 to 72
    • Eligibility criteria revised
    v10
  2. Study sites: 14 to 68v9
  3. Primary completion date: Dec 1, 2023 to Apr 1, 2025v8
  4. Primary completion date: Apr 1, 2023 to Dec 1, 2023
    • Study sites: 9 to 14
    • Eligibility criteria shortened, about 98 words
    v7
  5. Study sites: 8 to 9v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 2 to 8v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 15, 2021 to Jul 6, 2021
    • Site details revised at 2 of 2 sites
    v4
  3. Start date: Apr 1, 2021 to Jun 15, 2021v3
  4. Study sites: 1 to 2
    • Study title expanded, about 3 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The ABC-HCC trial is a Phase IIIb, randomised, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab plus bevacizumab versus TACE in patients with intermediate-stage HCC. Approximately 434 patients in two arms of treatment will be enrolled.
Trial Details
NCT Number NCT04803994
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Conditions
(from sponsor)		 Hepatocellular Carcinoma
Related terms Carcinoma, Hepatocellular
Enrollment 434 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov